Literature DB >> 21261637

Resveratrol: a cardioprotective substance.

Joseph M Wu1, Tze-chen Hsieh.   

Abstract

Coronary heart disease (CHD) is a major and preventable cause of morbidity and death in the United States. Recently, significant research efforts have been directed at an epidemiological phenomenon known as the "French paradox." This observation refers to the coexistence of high risk factors with unanticipated low incidence of CHD, and is postulated to be associated with low-to-moderate consumption of red wine. In vivo studies have shown that red wine intake is more CHD-preventative in comparison to other alcoholic drinks; enhanced cardioprotection may be attributed to grape-derived polyphenols, e.g., resveratrol, in red wine. This review summarizes results of in vitro and animal studies showing that resveratrol exerts multifaceted cardioprotective activities, as well as evidence demonstrating the presence of proteins specifically targeted by resveratrol, as exemplified by N-ribosyldihydronicotinamide:quinone oxidoreductase, NQO2. A mechanism encompassing nongenomic and genomic effects and a research roadmap is proposed as a framework for uncovering further insights on cardioprotection by resveratrol.
© 2011 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21261637     DOI: 10.1111/j.1749-6632.2010.05854.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  46 in total

Review 1.  Moderate ethanol ingestion and cardiovascular protection: from epidemiologic associations to cellular mechanisms.

Authors:  Maike Krenz; Ronald J Korthuis
Journal:  J Mol Cell Cardiol       Date:  2011-10-23       Impact factor: 5.000

2.  Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.

Authors:  Wei Li; Jiguang Ma; Qingyong Ma; Bin Li; Liang Han; Jiangbo Liu; Qinhong Xu; Wanxing Duan; Shuo Yu; Fengfei Wang; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 3.  Proteostasis and REDOX state in the heart.

Authors:  Elisabeth S Christians; Ivor J Benjamin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-14       Impact factor: 4.733

4.  Neuroprotective effect of resveratrol on ischemia/reperfusion injury in rats through TRPC6/CREB pathways.

Authors:  Yun Lin; Fang Chen; Jiancheng Zhang; Tingting Wang; Xin Wei; Jing Wu; Yinglu Feng; Zhongliang Dai; Qingping Wu
Journal:  J Mol Neurosci       Date:  2013-02-23       Impact factor: 3.444

Review 5.  Autophagy, myocardial protection, and the metabolic syndrome.

Authors:  Zoltan Giricz; Robert M Mentzer; Roberta A Gottlieb
Journal:  J Cardiovasc Pharmacol       Date:  2012-08       Impact factor: 3.105

Review 6.  Resveratrol and its impact on aging and thyroid function.

Authors:  L H Duntas
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

7.  Alcohol consumption and risk of death in male physicians with heart failure.

Authors:  Andrew B Petrone; J Michael Gaziano; Luc Djoussé
Journal:  Am J Cardiol       Date:  2014-07-18       Impact factor: 2.778

8.  Cardioprotective effects of red wine and vodka in a model of endothelial dysfunction.

Authors:  Antonio D Lassaletta; Louis M Chu; Nassrene Y Elmadhun; Thomas A Burgess; Jun Feng; Michael P Robich; Frank W Sellke
Journal:  J Surg Res       Date:  2012-06-21       Impact factor: 2.192

9.  Resveratrol levels and all-cause mortality in older community-dwelling adults.

Authors:  Richard D Semba; Luigi Ferrucci; Benedetta Bartali; Mireia Urpí-Sarda; Raul Zamora-Ros; Kai Sun; Antonio Cherubini; Stefania Bandinelli; Cristina Andres-Lacueva
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

Review 10.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.